Drug intelligence / Profile preview

5-fluorouracil + carmustine + cisplatin + cyclophosphamide + doxorubicin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous

Overview

This combination is a multi-agent chemotherapy regimen. Each component targets cancer cells differently: - 5-fluorouracil is an antimetabolite that interferes with DNA synthesis. - Carmustine is an alkylating agent that damages DNA. - Cisplatin is a platinum-based drug that cross-links DNA, preventing cell division. - Cyclophosphamide is an alkylating agent that interferes with DNA replication. - Doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II.

Targets

TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)

Beyond the preview

Go deeper on 5-fluorouracil + carmustine + cisplatin + cyclophosphamide + doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + carmustine + cisplatin + cyclophosphamide + doxorubicin.

Explore the full profile